

1 **Regulatory-approved Deep Learning/Machine Learning-Based Medical**

2 **Devices in Japan as of 2020: A Systematic Review**

3 Nao Aisu, M.D.¹, Masahiro Miyake, M.D., Ph.D., M.P.H.^{1,2*}, Kohei Takeshita, M.S.³,

4 Masato Akiyama, M.D., Ph.D.^{2,4}, Ryo Kawasaki, M.D., Ph.D., M.P.H.^{2,5}, Kenji Kashiwagi,

5 M.D., Ph.D.^{2,6}, Taiji Sakamoto, M.D., Ph.D.^{2,7}, Tetsuro Oshika M.D., Ph.D.^{2,8}, and Akitaka

6 Tsujikawa, M.D., Ph.D.¹

7

8 **Affiliations**

9 1, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of

10 Medicine, Kyoto, Japan

11 2, Japanese Society of Artificial Intelligence in Ophthalmology, Tokyo, Japan

12 3, Department of Innovation for Medical Information Technology, Jikei University School of

13 Tokyo, Tokyo, Japan

14 4, Department of Ocular Pathology and Imaging Science, Graduate School of Medical

15 Sciences, Kyushu University

16 5, Artificial Intelligence Center for Medical Research and Application, Osaka University

17 Hospital

18 6, Department of Ophthalmology, Faculty of Medicine, University of Yamanashi

19 7, Department of Ophthalmology, Kagoshima University Graduate School of Medical and

20 Dental Sciences

21 8, Department of Ophthalmology, Faculty of Medicine, University of Tsukuba

22

23 ***Corresponding Author:**

24 Masahiro Miyake, M.D., Ph.D. (Kyoto Univ.), M.P.H. (Harvard)

25 Department of Ophthalmology and Visual Sciences

26 Kyoto University Graduate School of Medicine

27 54 Shogoin, Kawahara, Sakyo, Kyoto 606-8507, Japan

28 Tel.: +81-75-751-3248

29 Fax: +81-75-752-0933

30

31 Board Member,

32 Japanese Society of Artificial Intelligence in Ophthalmology

33 3-10-5, Nihonbashi, Chuoku, Tokyo, 1038276, Japan

34 Tel.: +81-3-3510-3741

35 Fax: +81-3-3510-3748

36

37

38

39

40 **Abstract**

41 Machine learning (ML) and deep learning (DL) are changing the world and reshaping the
42 medical field. Thus, we conducted a systematic review to determine the status of
43 regulatory-approved ML/DL-based medical devices in Japan, a leading stakeholder in
44 international regulatory harmonization. Information about the medical devices were obtained
45 from the Japan Association for the Advancement of Medical Equipment search service. The
46 usage of ML/DL methodology in the medical devices was confirmed using public
47 announcements or by contacting the marketing authorization holders via e-mail when the
48 public announcements were insufficient for confirmation. Among the 114,150 medical
49 devices found, 11 were regulatory-approved ML/DL-based Software as a Medical Device
50 (SaMD), with 6 products (54.5%) related to radiology and 5 products (45.5%) related to
51 gastroenterology. The domestic ML/DL-based SaMD were mostly related to health
52 check-ups, which are common in Japan. Our review provides a global overview that can
53 foster international competitiveness and further tailored advancements.

54

55 **Introduction**

56 The ongoing fourth industrial revolution is mainly driven by the development of information
57 technology, computational power, and deep learning (DL), which is a method of machine
58 learning (ML). The fourth industrial revolution is changing the world in several aspects,
59 including the medical and healthcare fields. Thus, ML/DL-based technologies are expected to
60 transform the healthcare field by providing novel insights from the large amounts of data
61 generated from daily practice.¹⁻⁵ This technological application would improve disease
62 detection or diagnostic accuracy as well as aid the discovery of unprecedented observations
63 for personalized healthcare development.

64 In December 2016, a DL-based algorithm was first introduced in a major medical
65 journal.⁶ The algorithm demonstrated comparable accuracy to ophthalmologists in grading
66 diabetic retinopathy from fundus images. In the following year, reports emerged of a
67 dermatologist-level algorithm for classifying skin cancer into benign or malignant⁷ as well as
68 a pathologist-level algorithm for detecting a metastatic lesion of breast cancer from
69 hematoxylin and eosin-stained tissue sections of lymph nodes.⁸ Consequently, ML/DL
70 attracted considerable attention in the medical field, and more research papers on ML/DL
71 algorithms are being published (**Figure 1**).⁹⁻¹² Unlike the increasing number of ML/DL
72 studies,¹³ there are few regulator-approved, implemented ML/DL algorithms. For example, a
73 recent report noted that only 27 artificial intelligence (AI)/ML algorithms had been approved

74 by the Food and Drug Administration (FDA) in the United States before February 2020.¹⁴

75 Although this discrepancy is due to several reasons, the most prominent is that regulatory

76 authorities require the algorithms to have a high level of reliability in terms of clinical

77 effectiveness and safety; moreover, the regulatory authorities strictly check other factors,

78 such as the reliability of the training data and teacher labels as well as the validity of the

79 validation data and their use cases.

80 Currently, the regulatory authority of each country independently reviews the

81 application of AI-based medical devices because there are no harmonized regulatory

82 standards. However, harmonization is necessary, considering the growing importance of

83 AI-based medical devices that are utilized across borders. The International Council for

84 Harmonization (ICH) was launched in April 1990 to mobilize regulatory authorities and the

85 pharmaceutical industry for the development of global harmonization in pharmaceutical

86 regulations. The ICH was originally founded by the regulatory agencies and industry

87 associations of Europe, Japan, and the United States. The regulatory bodies of each

88 nationality (the European Medicine Agency (EMA), FDA, and the Japanese Pharmaceuticals

89 and Medical Devices Agency (PMDA)) collaborate as leading members of the ICH, which

90 currently includes 17 Members and 32 Observers worldwide. Harmonization in medical

91 devices regulation is also being discussed in the International Medical Device Regulators

92 Forum (IMDRF), of which Japan is also a founding member. IMDRF is expected to lead the

93 global harmonization of the regulatory standards of AI/ML-based medical devices and ensure
94 that safe, effective, and high-quality devices are developed, registered, and maintained in the
95 most resource-efficient manner.

96 As this is the dawn of AI-based medical devices, the state of regulatory-approved
97 AI-based medical devices in each country has not been sufficiently described; for instance,
98 only one review article has reported the status of the United States.¹⁴ Therefore, we
99 conducted a systematic review to describe the status of regulatory-approved ML/DL-based
100 medical devices in Japan, which is a leading member (alongside the United States and
101 European Union) of international regulatory harmonization.

102

103 **Methods**

104 We conducted a systematic review to determine the state of regulatory-approved
105 ML/DL-based algorithms for medical practice in Japan. Hence, we searched the Japan
106 Association for the Advancement of Medical Equipment search service (JAAME Search) to
107 obtain the data. JAAME Search is a paid electronic database for medical devices and consists
108 of 12 databases, including a database for the laws and regulations, notifications, package
109 insert, approval/certification, etc. We used the approval/certification database, which covers
110 almost all medical devices in Japan. As the first ML/DL-based algorithm in Japan is known
111 to have been approved in December 2018, the search focused on all Software as a Medical
112 Device (SaMD) that were certificated or approved between 1st December, 2018 and 31st
113 October, 2020 (accessed on 23rd November, 2020). From this database, we obtained
114 information such as generic name, marketing name, classification of device, applicant name,
115 application category, application type, date of approval/certification, and
116 approval/certification number.

117 Furthermore, we selected SaMD that were approved by the Minister of Health,
118 Labor and Welfare because all ML/DL-based SaMD require an approval by the Minister
119 regardless of their classification. This criterion is part of the Japanese regulation for
120 marketing approval of medical devices. In Japan, all Class III and Class IV medical devices
121 and a part of Class II medical devices require approval by the Minister of Health, Labor and

122 Welfare after a review by the PMDA. Whether a Class II medical device needs an approval
123 or not depends on certification standards: if the Minister of Health, Labor and Welfare has
124 established certification criteria for a medical device category, the device would not need an
125 approval; it would need certification instead. Because of the unprecedented nature of
126 ML/DL-based SaMD, ML/DL-based SaMD currently require an approval in Japan. A
127 comparison of the regulations for marketing approval of medical devices among Japan, US,
128 and EU are summarized in **Figure 2**.

129 The ML/DL-based SaMD were identified by referring to publicly accessible
130 information, including official websites, press-releases, academic papers, and package inserts.
131 If it was clear from the context that an SaMD employed any ML/DL method (e.g., support
132 vector machine (SVM), random forest, convolutional neural network, recurrent neural
133 network, generative adversarial network) within the scope of the approval, we considered the
134 product as an ML/DL-based algorithm. Thus, devices that adopted ML/DL algorithms
135 outside the scope of the approval were not regarded as ML/DL-based algorithms because the
136 ML/DL used in such devices were irrelevant to diagnosis or lesion detection. Regarding
137 devices for which we could not find publicly accessible information that clearly indicates the
138 usage of ML/DL, we contacted the responsible marketing authorization holder. We asked
139 them (1) to provide us the package insert, (2) whether the SaMD employs artificial
140 intelligence, and (3) to clarify the algorithm employed in the SaMD. If it was still unclear

141 whether the SaMD employed any ML/DL method, we considered the device as a
142 non-ML/DL-based algorithm. Similarly, if the marketing authorization holder refused to
143 provide information or did not respond to our e-mail within two weeks, we considered the
144 device as a non-ML/DL-based algorithm.

145 Finally, we reviewed each of the identified SaMD and summarized their
146 characteristics.

147

148 **Results**

149 The flow diagram of the result counts is presented in **Figure 3**. From the total of 114,150
150 approvals or certifications of medical devices registered in the JAAME database, we
151 identified 408 approvals or certifications of program devices. One hundred and twenty SaMD
152 (29.4%) were approved or certificated from December 1st, 2018 to October 31st, 2020.
153 Among these, 39 were approved, consisting of 22 (56.4%) Class II SaMD and 17 (43.6%)
154 Class III SaMD. Nine products were confirmed as ML/DL based on publicly available
155 information, and the other 30 products proceeded to direct query for the marketing
156 authorization holders. We received a reply for 28 products, and among them, 2 were
157 confirmed as ML/DL-based. Consequently, ML/DL-based SaMD were finally identified.

158 An overview of the ML/DL-based medical devices and algorithms is presented in
159 **Table 1**. The first approval was in December 2018, and it was the only ML/DL-based SaMD
160 approved in the year. This was followed by one approval in 2019 and nine more by the end of
161 October 2020. The number of ML/DL-based SaMD approvals in Japan is rapidly increasing,
162 following the trend of the US as shown in **Figure 4**. The figure illustrates a comparison
163 between the current approval number/year in Japan and the US. The status of the US refers to
164 the study conducted by Benjamens et al.¹⁴ The state of 2020 in the US is shown by the
165 simulated number from the study as it terminated in February 2020 unlike our study that
166 terminated in October 2020. Note that the study conducted by Benjamens et al. evaluated the

167 number of regulatory-approved AI/ML-based SaMD, whereas we evaluated
168 regulatory-approved ML/DL-based SaMD. This is because the term “artificial intelligence” is
169 too broad in meaning to represent the recent fourth industrial revolution. Even with
170 discrepancy in terminology between the two studies, the figure illustrates the trend of the
171 rapidly increasing Japanese approval number and the trend that follows the recent status of
172 the US.

173 As shown in Table 1, the medical specialties of regulatory-approved ML/DL-based
174 SaMD were biased to two areas: radiology and gastroenterology, with 6 products (54.5%)
175 and 5 products (45.5%) respectively. All algorithms were “locked” algorithms, i.e., an
176 algorithm that provides the same result each time with the same input and does not change or
177 adapt through real-world practice. Three (27.3%) of the devices were programs developed in
178 foreign companies and imported; the domestic marketing authorization holder applied for
179 approval. The other eight (72.7%) devices were domestically developed. All 11 devices were
180 developed for analyzing medical images, such as X-ray, computed tomography (CT), MRI,
181 and endoscopy. When categorized by their function, three (27.3%) were computer-aided
182 diagnosis (CADx) (EndoBrain[®], EndoBrain-UC[®], EndoBrain-Plus[®]), seven (63.6%) were
183 computer-aided detection (CADe) (EIRL aneurysm[®], FS-AI688[®], InferRead CT Pneumonia[®],
184 AI-Rad Companion[®], EndoBrain-EYE[®], Ali-M3[®], EIRL X-Ray Lung nodule[®]), and the
185 remaining one (9%) combined both functions of CADx and CADe (EW10-EC02[®]).

186 The first regulatory-approved AI/ML SaMD in Japan was EndoBrain[®], which
187 supports the endoscopists’ real-time diagnosis of “neoplastic polyps” or “non-neoplastic
188 polyps” during colonoscopy check-ups. By analyzing the images of the lesion taken with an
189 ultra-magnification colonoscope using SVM algorithm, the possibility of being neoplastic or
190 non-neoplastic is displayed as a percentage. The sensitivity of the device was reportedly
191 96.8%, and its accuracy was 98.0%.^{15,16} EIRL aneurysm[®] is a CADe software for detecting
192 brain aneurysms (diameter \geq 2 mm) from brain MRA images. This software can support the
193 diagnosis of unruptured cerebral aneurysms at brain check-ups by increasing the sensitivity to
194 detect aneurysms from 68.2% to 77.2%.¹⁷ EndoBrain-UC[®] is a software for predicting the
195 presence or absence of intestinal inflammation (active phase or remission phase) from the
196 ultra-magnified colonoscope images of patients with ulcerative colitis. It could find the
197 remission phase with a sensitivity of 89.5%, specificity of 99.1%, and accuracy of 92%.
198 FS-AI688 is a CADe software for supporting lung nodule detection from lung CT images of
199 suspected lung cancer patients, and it displays marks on possible lung nodules. Both
200 InferRead CT Pneumonia[®] and Ali-M3[®] are DL-based CADe programs for detecting
201 COVID-19 pneumonia from chest CT images in three probability grades; the devices were
202 developed in China. AI-Rad Companion[®] is a series of imaging supportive software, of
203 which “the Chest CT image contract service” is the only product approved in Japan. This
204 software can detect and quantify abnormalities of multiple areas of the body, such as the

205 lungs, heart, and aorta, from chest CT images. EndoBrain-EYE[®] is a polyp detection program
206 for regular colonoscopy check-ups. When the device detects a candidate lesion for polyp or
207 cancer in the real-time colonoscopy images, it alerts the colonoscopists with sounds and
208 colors on the screen. A sensitivity of 95% and specificity of 89% were reported for the
209 device.¹⁸ EndoBrain-Plus[®] analyzes images of the lesion acquired using an ultra-magnifying
210 colonoscope under methylene blue staining during colonoscopy check-ups. The system
211 displays in real-time the probability of the lesion to be “non-neoplastic,” “adenoma,”
212 “intramucosal carcinoma,” or “invasive carcinoma.” Its performance to detect invasive
213 carcinoma is reported to be 91.8% of sensitivity and 97.3% of specificity. EIRL X-Ray Lung
214 nodule[®] detects suspected pulmonary nodules (5 mm to 30 mm) on chest x-ray images. This
215 CADe is reported to increase a sensitivity to detect lung nodules by 9.9 percentage points for
216 radiologists and 13.1 percentage points for non-specialists. EW10-EC02 is a software for
217 colonoscopy, which supports lesion detection, such as polyps, by framing the suspected
218 lesion on the monitor and alerting with sounds. The device can also differentiate the lesion as
219 neoplastic or non-neoplastic. These functionalities of the device operate in real-time during
220 colonoscopy.
221

222 **Discussion**

223 The implementation of ML/DL in medical devices is advancing swiftly as ML/DL
224 demonstrates high prospects in improving clinical outcomes and public health, and it is
225 cost-effective.^{19,20} In these early stages of the ML/DL era, we aimed to highlight the state of
226 regulatory-approved ML/DL-based SaMD in Japan whose regulatory body, PMDA, is one of
227 the leading members of international regulatory harmonization alongside Europe's EMA and
228 the United States' FDA. Our study showed that 11 AI/ML-based SaMD had been approved in
229 Japan as of October 2020.

230 In comparison to the US approval status reported by Benjamins, et.al.¹⁴, the field of
231 radiology is a trendsetter of ML/DL-based SaMD in both countries as SaMD related to
232 radiology was the most approved both in Japan and the US with 54.5% and 72.4%,
233 respectively. This is probably due to the image-intensive nature of radiology, and DL
234 technology has high affinity to imaging. Conversely, a prominent feature of the Japanese
235 approval status is that gastroenterology was second (45.5%) to radiology in the
236 implementation of ML/DL in the medical field, whereas the FDA-approved devices next to
237 radiology were in cardiology, internal medicine/endocrinology, neurology, ophthalmology,
238 emergency medicine, and oncology. The EndoBrain[®] series occupies four of five
239 regulatory-approved endoscopy-related ML/DL-based SaMD, which were developed with
240 funding from the Japan Agency for Medical Research and Development (AMED), technical

241 support from Cybernet, and endoscopic technology and commercialization from Olympus.
242 Olympus is a Japanese company occupying 70% of the world market share for endoscopes.
243 The technology to enhance image resolution with ultra-magnification colonoscopes and their
244 powerful sales channel is believed to have been a major driving force behind the
245 implementation of ML/DL technology in this field. Another unique device among the
246 domestic devices is EIRL aneurysm[®], an algorithm to detect “unruptured” aneurisms from
247 MRA images. Although several algorithms have been developed in other countries that
248 support the detection of acute lesion, such as cerebral injury or hemorrhage using MRI, EIRL
249 aneurysm[®] is unique because it focuses on the precursor lesion placing MRI as a health
250 check-up tool. This was approved relatively early, meaning the demand for the product was
251 high. As Japan is a global leader in MRI possession, “Brain check-up” is becoming more
252 popular among Japanese citizens because of its accessibility and affordability. This situation
253 likely facilitated the implementation of this technology.

254 The first autonomous diagnostic device approved by the FDA (April 2018) was a
255 diabetic retinopathy screening device (IDx-DR[®], Digital Diagnostics) that was recently
256 followed by a similar device approved in August 2020 (EyeArt[®], EYENUK). In contrast,
257 there have been no regulatory-approved ML/DL-based SaMD in the field of ophthalmology
258 in Japan. This difference may be related to the social need as Japan has easier medical access
259 with the availability of several medical practitioners in local clinics as well as universal

260 health coverage. Nevertheless, as the Japanese Ocular Imaging registry was established as a
261 platform for industry-university collaboration, similar to the Intelligent Research in Sight
262 registry of the American Academy of Ophthalmology, the number of ML/DL-based
263 ophthalmological device will hopefully increase. Building a platform for AI utilization is an
264 important issue in every country, and Japan is moving toward the realization.

265 Apparently, AI-based SaMD are closely related to society. Thus, focusing on the
266 public needs or industrial strengths of each country can lead to a more competitive and
267 unique development when seeking a global market. For example, because of the increasing
268 public health awareness and easy access to medicine, health check-ups are popular in Japan.
269 Most ML/DL-based SaMD approved in Japan were programs that targeted check-ups rather
270 than a specialized or specific medical practice. Moreover, the high proportion of
271 ML/DL-based SaMD related to endoscopy in Japan reflects Japan's industrial strength in
272 endoscopic systems. It is important for each country to scrutinize the public demand and
273 industrial situation to facilitate the implementation of AI. Knowledge of the developmental
274 background is also crucial when considering the implementation of a foreign device as most
275 ML/DL-based medical devices will probably be exported after domestic commercialization.
276 Imported products may not work well due to differences in backgrounds (e.g., social needs,
277 health insurance system, etc.), even if the product is dominant in other countries. Therefore,
278 the approval situation and background information of the innovation can be an important

279 information that suggest how to adopt imported ML/DL-based devices. Therefore, it is

280 worthwhile to investigate the developmental situation of SaMD in each country.

281 In this systematic review, we report on the regulatory-approved ML/DL-based
282 SaMD in Japan. Our review provides an overview of the global developmental situation of
283 ML/DL-based medical devices, considering the current lack of relevant information about
284 such devices. As ML/DL-based SaMD are closely related to the industrial and cultural
285 backgrounds of each country, development that is focused on the strengths of each country
286 can lead to international competitiveness. Additionally, the maximization of the capabilities
287 of AI requires a consideration of the strengths in each country and creation of a platform for
288 more active developments.

289

290

291

292 **Figure Legend**

293 **Figure 1. Transition of the number of publications regarding machine learning or deep**
294 **learning in PubMed.**

295 (A) Transition of the number of machine-learning-related publications. The search query was
296 (Machine learning) AND (("2015/1/1"[Date - Publication] : "2020/12/31"[Date -
297 Publication])) (accessed at 2, February, 2021). (B) Transition of the number of
298 deep-learning-related publications. The search query was (Deep learning) AND
299 (("2015/1/1"[Date - Publication] : "2020/12/31"[Date - Publication])) (accessed at 2,
300 February, 2021). Publications regarding machine learning or deep learning are rapidly
301 increasing in PubMed.

302

303 **Figure 2. Comparison of the regulation for marketing approval of medical devices**
304 **among the United States, Japan, and European Union.**

305 The figure illustrates the regulatory status of the three nationalities based on the classification
306 of medical devices. In Japan, medical devices of class III or more and those of class II for
307 which certification standards do not exist (e.g., artificial intelligence (AI) medical devices as
308 of 2020) require the review of Pharmaceuticals and Medical Devices Agency as well as the
309 approval of the Ministry of Health, Labour, and Welfare. A software that corresponds to class
310 I medical device is not treated as medical device in Japan. FDA: Food and Drug

311 Administration; PMDA: Japanese Pharmaceuticals and Medical Devices Agency; MHLW:

312 Ministry of Health, Labour, and Welfare.

313

314 **Figure 3. Flow diagram of identifying the applicable Software as a Medical Device**

315 **(SaMD).**

316 From the total of 114,150 medical devices in the Japan Association for the Advancement of

317 Medical Equipment (JAAME) search database accessed on 23rd November 2020, we have

318 identified 408 SaMD. Among these, 120 were certificated or approved from December 1st,

319 2018 to October 31st, 2020 and 39 were approved SaMD. Products with a clear statement of

320 ML/DL usage or with the confirmation from the marketing authorization holder were

321 considered as ML/DL-based. 11 ML/DL-based SaMD were finally identified.

322

323 **Figure 4. Comparison of the approval status of machine learning/deep learning-based**

324 **software as a medical device (SaMD) between Japan and the United States.**

325 The figure illustrates a comparison between the current approval number/year in Japan and

326 the US. The status of the US refers to the study conducted by Benjamens et al.¹⁴ The state of

327 2020 in the US is shown by the simulated number from the study as it terminated in February

328 2020 unlike our study that terminated in October 2020. Note that the study conducted by

329 Benjamens et al. evaluated the number of regulatory-approved AI/ML-based SaMD, whereas

330 we evaluated regulatory-approved ML/DL-based SaMD. This is because the term “artificial
331 intelligence” is too broad in meaning to represent the recent fourth industrial revolution. Even
332 with discrepancy in terminology between the two studies, the figure illustrates the trend of
333 the rapidly increasing Japanese approval number and the trend that follows the recent status
334 of the US.

335

336

337 **Financial Support:** This research was supported by AMED under Grant Number
338 JP20vk0124003. This research was also supported by MHLW ICT infrastructure
339 establishment and implementation of artificial intelligence for clinical and medical research
340 program, Grant Number JP20AC0201.

341

342

343 **Conflict of Interest:** No conflicting relationship exists for any author.

344

345

346 **Acknowledgements**

347 We would like to thank the marketing authorization holders for collaborating by answering
348 our query on the early stage of this work.

349

350 **Author Contributions**

351 NA, MM were involved in study design. NA, KT were involved in data collection. NA, MM,

352 MA, RK, KK, TS, TO, and AT were involved in data interpretation. All authors critically

353 revised the manuscript, approved the manuscript to be published, and agreed to be

354 accountable for all aspects of the work ensuing that questions related to the accuracy or

355 integrity of any part of the work are appropriately investigated and resolved.

356

357

358 **Data Availability**

359 Data that support the findings of this study are available in the JAMME search repository,

360 <https://search.jaame.or.jp/jaames/login.php>



361

362 **References**

- 363 1 Hosoda, Y. *et al.* Deep phenotype unsupervised machine learning revealed the
364 significance of pachychoroid features in etiology and visual prognosis of age-related
365 macular degeneration. *Sci. Rep.* **10**, 18423, doi:10.1038/s41598-020-75451-5 (2020).
- 366 2 Hosoda, Y. *et al.* Keratoconus-susceptibility gene identification by corneal thickness
367 genome-wide association study and artificial intelligence IBM Watson. *Commun. Biol.*
368 **3**, 410, doi:10.1038/s42003-020-01137-3 (2020).
- 369 3 Stead, W. W. Clinical Implications and Challenges of Artificial Intelligence and Deep
370 Learning. *JAMA* **320**, 1107-1108, doi:10.1001/jama.2018.11029 (2018).
- 371 4 Topol, E. J. High-performance medicine: the convergence of human and artificial
372 intelligence. *Nat. Med.* **25**, 44-56, doi:10.1038/s41591-018-0300-7 (2019).
- 373 5 Verghese, A., Shah, N. H. & Harrington, R. A. What This Computer Needs Is a
374 Physician: Humanism and Artificial Intelligence. *JAMA* **319**, 19-20,
375 doi:10.1001/jama.2017.19198 (2018).
- 376 6 Gulshan, V. *et al.* Development and Validation of a Deep Learning Algorithm for
377 Detection of Diabetic Retinopathy in Retinal Fundus Photographs. *JAMA* **316**,
378 2402-2410, doi:10.1001/jama.2016.17216 (2016).
- 379 7 Esteva, A. *et al.* Dermatologist-level classification of skin cancer with deep neural
380 networks. *Nature* **542**, 115-118, doi:10.1038/nature21056 (2017).

- 381 8 Bejnordi, B. E. *et al.* Diagnostic Assessment of Deep Learning Algorithms for
382 Detection of Lymph Node Metastases in Women With Breast Cancer. *JAMA* **318**,
383 2199-2210, doi:10.1001/jama.2017.14585 (2017).
- 384 9 Phan, S. *et al.* Evaluation of deep convolutional neural networks for glaucoma
385 detection. *Jpn. J. Ophthalmol.* **63**, 276-283, doi:10.1007/s10384-019-00659-6 (2019).
- 386 10 Otsuki, R. *et al.* Deep Learning Model to Predict Postoperative Visual Acuity from
387 Preoperative Multimedia Ophthalmic Data. *Adv. Biomed. Eng.* **9**, 241-248,
388 doi:10.14326/abe.9.241 (2020).
- 389 11 Kaul, V., Enslin, S. & Gross, S. A. History of artificial intelligence in medicine.
390 *Gastrointest. Endosc.* **92**, 807-812, doi:10.1016/j.gie.2020.06.040 (2020).
- 391 12 Caruana, R. *et al.* in *Proceedings of the 21th ACM SIGKDD International Conference*
392 *on Knowledge Discovery and Data Mining - KDD '15* 1721-1730 (2015).
- 393 13 Litjens, G. *et al.* A survey on deep learning in medical image analysis. *Med. Image*
394 *Anal.* **42**, 60-88, doi:10.1016/j.media.2017.07.005 (2017).
- 395 14 Benjamens, S., Dhunoo, P. & Mesko, B. The state of artificial intelligence-based
396 FDA-approved medical devices and algorithms: an online database. *NPJ Digit. Med.*
397 **3**, 118, doi:10.1038/s41746-020-00324-0 (2020).
- 398 15 Kudo, S. E. *et al.* Artificial Intelligence-assisted System Improves Endoscopic
399 Identification of Colorectal Neoplasms. *Clin. Gastroenterol. Hepatol.* **18**, 1874-1881

- 400 e1872, doi:10.1016/j.cgh.2019.09.009 (2020).
- 401 16 Mori, Y. *et al.* Real-Time Use of Artificial Intelligence in Identification of Diminutive
402 Polyps During Colonoscopy: A Prospective Study. *Ann. Intern. Med.* **169**, 357-366,
403 doi:10.7326/M18-0249 (2018).
- 404 17 Ueda, D. *et al.* Deep Learning for MR Angiography: Automated Detection of Cerebral
405 Aneurysms. *Radiology* **290**, 187-194, doi:10.1148/radiol.2018180901 (2019).
- 406 18 Misawa, M. *et al.* Artificial Intelligence-Assisted Polyp Detection for Colonoscopy:
407 Initial Experience. *Gastroenterology* **154**, 2027-2029 e2023,
408 doi:10.1053/j.gastro.2018.04.003 (2018).
- 409 19 Matheny, M. E., Whicher, D. & Israni, S. T. Artificial Intelligence in Health Care: A
410 Report From the National Academy of Medicine. *JAMA* **323**, 509-510,
411 doi:10.1001/jama.2019.21579 (2020).
- 412 20 London, A. J. Artificial Intelligence and Black-Box Medical Decisions: Accuracy
413 versus Explainability. *Hastings Cent. Rep.* **49**, 15-21, doi:10.1002/hast.973 (2019).
- 414
- 415
- 416
- 417



Country [Regulator]	Medical Devices Classification			
The United States [FDA]	Class I	Class II		Class III
Japan [Review: PMDA] [Approval: MHLW]	Class I	Class II	Class III	Class IV
The European Union [Notification Body]	Class I	Class II a	Class II b	Class III

Medical devices for which certification standards do not exist [e.g., AI medical devices as of 2020]



needs approval



needs third-party certification



needs notification / self-certification

Total approvals/certifications of
medical devices
registered in JAMME database
N=114,150



Total approvals/certifications of SaMD
N=408



Approved/certificated during
targeted period (Dec 2018 to Oct 2020)
N=120



Approval
N=39



**Able to confirm the usage of
ML/DL from public
announcement**

YES

**ML/DL-based SaMD
N=9**

NO

Insufficient information
N=30



**Able to confirm the usage of
ML/DL by contacting
marketing authorization
holder via Email**

YES

**ML/DL-based SaMD
N=2**

NO

Unable to confirm the usage of ML/DL
N=28

Annual trend of regulatory-approved AI-based SaMD




Table1. Overview of the ML/DL-based medical devices and algorithms approved in Japan

No.	Device name	Short description	Class	Company name	Application distinction	Approval date	PMDA approval number	Medical specialty	Algorithm	CAD	Country	Image type
1	EW10-EC02	Lesion detection and diagnosis during colonoscopy	III	FUJIFILM	approved	2-Sep-20	30200BZX00288000	Gastroenterology	deep learning	CADe +CADx	Japan	endoscopy
2	EIRL X-Ray Lung nodule	Lung cancer detection	II	LPIXEL	approved	20-Aug-20	30200BZX00269000	Radiology	deep learning (CNN)	CADe	Japan	X-ray
3	EndoBRAIN Plus	Pathological prediction during colonoscopy	III	CYBERNET	approved	15-Jul-20	30200BZX00235000	Gastroenterology	Machine learning (SVM)	CADx	Japan	endoscopy
4	Ali-M3	COVID-19 pneumonia detection	II	MIC Medical Corp.	approved	29-Jun-20	30200BZX00212000	Radiology	deep learning	CADe	China	CT
5	EndoBRAIN EYE	Polyp detection during colonoscopy	II	CYBERNET	approved	29-Jun-20	30200BZX00208000	Gastroenterology	deep learning	CADe	Japan	endoscopy
6	AI-Rad companion (Chest CT)	Detects and quantifies abnormalities of the chest CT	II	Siemens Healthineers Japan	approved	19-Jun-20	30200BZX00202000	Radiology	deep learning	CADe	Germany US	CT
7	InferRead CT Pneumonia	COVID-19 pneumonia detection	II	CES decartes	approved	3-Jun-20	30200BZX00184000	Radiology	deep learning (CNN)	CADe	China	CT
8	FS-AI688	Lung cancer detection	II	FUJIFILM	approved	8-May-20	30200BZX00150000	Radiology	deep learning	CADe	Japan	CT
9	EndoBRAIN UC	Inflammation assessment support for Ulcerative Colitis	III	CYBERNET	approved	27-Apr-20	30200BZX00136000	Gastroenterology	machine learning (SVM)	CADx	Japan	endoscopy
10	EIRL aneurysm	Cerebral aneurysm detection	II	LPIXEL	approved	17-Sep-19	30100BZX00142000	Radiology	deep learning (CNN)	CADe	Japan	MRI
11	EndoBRAIN	Pathological prediction during colonoscopy	III	CYBERNET	approved	6-Dec-18	23000BZX00372000	Gastroenterology	machine learning (SVM)	CADx	Japan	endoscopy

CNN: convolutional neural network, SVM: support vector machine, CADe: computer-aided detection, CADx: computer-aided diagnosis; PMDA: Pharmaceuticals and Medical Devices Agency (Japan)